Rapid Medical’s DRIVEWIRE 35 received FDA clearance as the first steerable 0.035-inch guidewire for stroke, neurovascular, and peripheral access. The company cites performance after 5,000 DW24 cases, supporting its clinical adoption. While positive for product credibility, the news is unlikely to be broadly market-moving.
Rapid Medical’s DRIVEWIRE 35 received FDA clearance as the first steerable 0.035-inch guidewire for stroke, neurovascular, and peripheral access. The company cites performance after 5,000 DW24 cases, supporting its clinical adoption. While positive for product credibility, the news is unlikely to be broadly market-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
